This article is more than 5 years old. Information may no longer be current.

First-ever lung cancer, melanoma research collaboration announced

The LUNGevity Foundation has announced a partnership with the Lung Cancer Research Foundation and the Melanoma Research Alliance to fund new research on PD-1 inhibitor treatment options for non-small cell lung cancer and metastatic melanoma patients with brain metastases.

The recipient of this award is Lucia Jilaveanu, MD, PhD, of Yale University, for her project entitled, “Response to PD-1 Inhibitors in Melanoma and Lung Cancer Patients with Brain Metastases.”

Approximately 50,000 patients develop brain metastases each year; this first-ever research collaboration between lung cancer and melanoma organizations indicates the urgency of this issue, according to a LUNGevity Foundation press release.

Individuals with non-small cell lung cancer have the highest incidence of brain metastases among all cancers, and melanoma has the highest likelihood to metastasize to the brain once the disease has spread, the release said.

For more information on the LUNGevity Foundation, visit www.LUNGevity.org.